Yoram Palti Sells 60,000 Shares of NovoCure (NVCR) Stock

NovoCure (NASDAQ:NVCR) insider Yoram Palti sold 60,000 shares of the stock in a transaction on Tuesday, April 3rd. The shares were sold at an average price of $20.32, for a total transaction of $1,219,200.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Yoram Palti also recently made the following trade(s):

How to Become a New Pot Stock Millionaire
  • On Thursday, March 29th, Yoram Palti sold 30,000 shares of NovoCure stock. The shares were sold at an average price of $21.67, for a total transaction of $650,100.00.

Shares of NVCR opened at $19.85 on Friday. The firm has a market cap of $1,829.11, a price-to-earnings ratio of -28.36 and a beta of 3.16. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.88 and a quick ratio of 4.44. NovoCure has a twelve month low of $10.30 and a twelve month high of $24.15.

NovoCure (NASDAQ:NVCR) last announced its quarterly earnings results on Thursday, February 22nd. The medical equipment provider reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The business had revenue of $53.66 million during the quarter, compared to analysts’ expectations of $53.17 million. NovoCure had a negative net margin of 34.83% and a negative return on equity of 51.74%. The firm’s revenue for the quarter was up 77.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.26) EPS. equities research analysts forecast that NovoCure will post -0.5 EPS for the current fiscal year.

Several research firms recently commented on NVCR. ValuEngine raised shares of NovoCure from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised shares of NovoCure from a “sell” rating to a “hold” rating in a report on Friday, March 9th. Zacks Investment Research lowered shares of NovoCure from a “buy” rating to a “hold” rating in a report on Saturday, January 13th. Mizuho reaffirmed a “buy” rating and set a $28.00 target price (up previously from $25.00) on shares of NovoCure in a report on Friday, February 23rd. Finally, Deutsche Bank reduced their target price on shares of NovoCure from $22.00 to $19.00 and set a “hold” rating on the stock in a report on Friday, February 23rd. Four investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $19.71.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Farallon Capital Management LLC purchased a new stake in NovoCure during the 4th quarter valued at $23,533,000. Frontier Capital Management Co. LLC boosted its position in NovoCure by 29.8% during the 4th quarter. Frontier Capital Management Co. LLC now owns 1,081,898 shares of the medical equipment provider’s stock valued at $21,854,000 after buying an additional 248,322 shares during the period. Tamarack Advisers LP purchased a new stake in NovoCure during the 4th quarter valued at $21,311,000. Peregrine Capital Management LLC boosted its position in NovoCure by 38.0% during the 4th quarter. Peregrine Capital Management LLC now owns 865,671 shares of the medical equipment provider’s stock valued at $17,487,000 after buying an additional 238,195 shares during the period. Finally, Allianz Asset Management GmbH purchased a new stake in NovoCure during the 4th quarter valued at $10,760,000. 42.83% of the stock is owned by institutional investors and hedge funds.

WARNING: “Yoram Palti Sells 60,000 Shares of NovoCure (NVCR) Stock” was posted by Ticker Report and is owned by of Ticker Report. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The correct version of this story can be read at https://www.tickerreport.com/banking-finance/3337300/yoram-palti-sells-60000-shares-of-novocure-nvcr-stock.html.

NovoCure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Relx PLC  Plans Dividend of GBX 27.70
Relx PLC Plans Dividend of GBX 27.70
Trident Group  Price Tops $0.18 on Exchanges
Trident Group Price Tops $0.18 on Exchanges
Man Group Plc  Plans Dividend of GBX 4.18
Man Group Plc Plans Dividend of GBX 4.18
Corethum  Reaches 1-Day Volume of $0.00
Corethum Reaches 1-Day Volume of $0.00
FUNCoin  Price Tops $0.0177 on Exchanges
FUNCoin Price Tops $0.0177 on Exchanges
Comparing Haynes International  & Gerdau
Comparing Haynes International & Gerdau


© 2006-2018 Ticker Report. Google+.